Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, et al.
Haematologica (2018) Vol. 104, Iss. 4, pp. 797-804
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

High Expression Levels of the Long Non-Coding RNAs Lnc-IRF2-3 and Lnc-KIAA1755-4 Are Markers of Poor Prognosis in Chronic Lymphocytic Leukemia
Nataša Tos̆ić, Kristina Tomić, Vojin Vuković, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1153-1153
Open Access
Comparative efficacy of venetoclax-based regiments in the management of chronic lymphocytic leukemia: a systematic review and metanalysis
Abdur Jamil, Shehroz Aslam, Rida Riaz, et al.
Annals of Hematology (2025)
Open Access
VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance
Weiling Liu, Chuanwang Miao, Shaosen Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 26
IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study
Emelie Curovic Rotbain, Henrik Frederiksen, Henrik Hjalgrim, et al.
Haematologica (2019) Vol. 105, Iss. 6, pp. 1621-1629
Open Access | Times Cited: 27
Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017
Rudolf Weide, Stefan Feiten, Geothy Chakupurakal, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2019) Vol. 61, Iss. 3, pp. 557-566
Open Access | Times Cited: 25
A decade of chronic lymphocytic leukaemia therapy in Germany: Real‐world treatment patterns and outcomes (2010–2022)
Hannes Wartmann, Anna Kabilka, Barthold Deiters, et al.
eJHaem (2024) Vol. 5, Iss. 2, pp. 346-352
Open Access | Times Cited: 2
Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden
Kari Hemminki, Frantisek Zitricky, Asta Försti, et al.
Cancers (2024) Vol. 16, Iss. 18, pp. 3229-3229
Open Access | Times Cited: 2
Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany
Hiltraud Kajüter, Ina Wellmann, Laura Khil, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 10
Open Access | Times Cited: 17
Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia
Tian Zheng, Ming Liu, Xiaosheng Fang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review
Stephen Jolles, Sergio Giralt, Tessa Kerre, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Emerging treatment options for patients with p53-pathway-deficient CLL
Marisa J.L. Aitken, Hun Ju Lee, Sean M. Post
Therapeutic Advances in Hematology (2019) Vol. 10
Open Access | Times Cited: 18
Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves
Neda Alrawashdh, Daniel O. Persky, Ali McBride, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 11, pp. e820-e831
Closed Access | Times Cited: 13
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
Lukáš Smolej, Pavel Vodárek, Dominika Écsiová, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3134-3134
Open Access | Times Cited: 11
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation‐wide real‐world report on consecutively identified patients
Agnes Mattsson, Sandra Eketorp Sylvan, Per Axelsson, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 5, pp. 715-721
Open Access | Times Cited: 4
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
Javier Loscertales, Pau Abrisqueta-Costa, Antonio Gutiérrez, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4047-4047
Open Access | Times Cited: 4
The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review
Kevin Li, Mohammad Kaker, Jerry Lau, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 5, pp. 480-489
Open Access | Times Cited: 1
Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
Agnes Mattsson, Sandra Eketorp Sylvan, Anna Asklid, et al.
British Journal of Haematology (2020) Vol. 191, Iss. 3, pp. 426-432
Open Access | Times Cited: 8
Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center
Juha Ranti, Katariina Perkonoja, Tommi Kauko, et al.
eJHaem (2021) Vol. 3, Iss. 1, pp. 291-300
Open Access | Times Cited: 7
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy
Anna Asklid, Sandra Eketorp Sylvan, Agnes Mattsson, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 61, Iss. 9, pp. 2136-2144
Closed Access | Times Cited: 6
Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel
Clara Weil, Gabriel Chodick, Varda Shalev, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 62, Iss. 5, pp. 1136-1145
Closed Access | Times Cited: 6
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
Jung‐Sun Kim, Tae Min Kim, Myoung Joo Kang, et al.
The Korean Journal of Internal Medicine (2023) Vol. 38, Iss. 5, pp. 747-757
Open Access | Times Cited: 2
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
Jun Ho Yi, Gyeong‐Won Lee, Ji Hyun Lee, et al.
Blood Research (2021) Vol. 56, Iss. 4, pp. 243-251
Open Access | Times Cited: 4
Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005‐2015 show improved survival over time
Vesa Lindström, Katja M. Hakkarainen, Juha Mehtälä, et al.
European Journal Of Haematology (2019) Vol. 103, Iss. 3, pp. 190-199
Open Access | Times Cited: 3
Pregnancy in a 31-year-old woman with chronic lymphocytic leukemia: a case report and review of the literature
Nigel P Murray, Shenda Orrego, Marco Antonio López, et al.
Hematology Transfusion and Cell Therapy (2020) Vol. 43, Iss. 3, pp. 368-370
Open Access | Times Cited: 3
Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal—Results from a population-based cancer registry cohort study
F. Borges, Adriana Ramos, António Lourenço, et al.
PLoS ONE (2021) Vol. 16, Iss. 10, pp. e0258423-e0258423
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top